Literature DB >> 17712071

Underdiagnosis of hypertension in children and adolescents.

Matthew L Hansen1, Paul W Gunn, David C Kaelber.   

Abstract

CONTEXT: Pediatric hypertension is increasing in prevalence with the pediatric obesity epidemic. Diagnosis of hypertension in children is complicated because normal and abnormal blood pressure values vary with age, sex, and height and are therefore difficult to remember.
OBJECTIVES: To determine the frequency of undiagnosed hypertension and prehypertension and to identify patient factors associated with this underdiagnosis. DESIGN, SETTING, AND PARTICIPANTS: A cohort study of 14,187 children and adolescents aged 3 to 18 years who were observed at least 3 times for well-child care between June 1999 and September 2006 in the outpatient clinics in a large academic urban medical system in northeast Ohio. For children and adolescents who met criteria for hypertension or prehypertension at 3 or more well-child care visits, the proportion with a hypertension-related International Classification of Diseases, Ninth Revision code in the diagnoses list, problem list, or past medical history list of any visit was determined. MAIN OUTCOME MEASURES: Proportion of children and adolescents with 3 or more elevated age-adjusted and height-adjusted blood pressure measurements at well-child care visits and with a diagnosis of hypertension or prehypertension documented in the electronic medical record. Multivariate logistic regression identified patient factors associated with a correct diagnosis.
RESULTS: Of 507 children and adolescents (3.6%) who had hypertension, 131 (26%) had a diagnosis of hypertension or elevated blood pressure documented in the electronic medical record. Patient factors that increased the adjusted odds of a correct diagnosis were a 1-year increase in age over age 3 (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.03-1.16), number of elevated blood pressure readings beyond 3 (OR, 1.77; 95% CI, 1.21-2.57), increase of 1% in height-for-age percentile (OR, 1.02; 95% CI, 1.01-1.03), having an obesity-related diagnosis (OR, 2.61; 95% CI, 1.49-4.55), and number of blood pressure readings in the stage 2 hypertension range (OR, 1.68; 95% CI, 1.29-2.19). Of 485 children and adolescents (3.4%) who had prehypertension, 55 (11%) had an appropriate diagnosis documented in the electronic medical record. Patient factors that increased the adjusted odds of being diagnosed with prehypertension included a 1-year increase in age over age 3 (OR, 1.21; 95% CI, 1.09-1.34) and number of elevated blood pressure readings beyond 3 (OR, 3.07; 95% CI, 2.20-4.28).
CONCLUSIONS: Hypertension and prehypertension were frequently undiagnosed in this pediatric population. Patient age, height, obesity-related diagnoses, and magnitude and frequency of abnormal blood pressure readings all increased the odds of diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17712071     DOI: 10.1001/jama.298.8.874

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  244 in total

1.  Chronic mercury exposure and blood pressure in children and adolescents: a systematic review.

Authors:  Gema Gallego-Viñas; Ferran Ballester; Sabrina Llop
Journal:  Environ Sci Pollut Res Int       Date:  2018-12-06       Impact factor: 4.223

2.  Antihypertensive prescribing patterns for adolescents with primary hypertension.

Authors:  Esther Y Yoon; Lisa Cohn; Albert Rocchini; David Kershaw; Gary Freed; Frank Ascione; Sarah Clark
Journal:  Pediatrics       Date:  2011-12-05       Impact factor: 7.124

3.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

4.  Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension: profile report.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

5.  Olmesartan medoxomil in children and adolescents with hypertension†: profile report.

Authors:  Victoria J Muir; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

6.  Screening blood pressure measurement in children: are we saving lives?

Authors:  Tammy M Brady; Karen M Redwine; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

7.  Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care.

Authors:  Christie M Bartels; Heather Johnson; Katya Voelker; Carolyn Thorpe; Patrick McBride; Elizabeth A Jacobs; Nancy Pandhi; Maureen Smith
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-09       Impact factor: 4.794

8.  Recognition and Management of Elevated Blood Pressure in Pediatric Patients: Challenges and Disparities in Community Health Centers.

Authors:  Rikki L Ward; Jessica M Robbins; Rebecca N Haden; Brittany J Benson; Issy C Esangbedo
Journal:  J Community Health       Date:  2016-04

9.  Management of Hypertension and High Low-Density Lipoprotein in Pediatric Type 1 Diabetes.

Authors:  Michelle L Katz; Zijing Guo; Lori M Laffel
Journal:  J Pediatr       Date:  2018-02-01       Impact factor: 4.406

10.  Time to referral to a nephrology clinic for pediatric hypertension.

Authors:  Tyler Hamby; Matthew R Pueringer; Sahil Noorani; Alisha Khanna; Julie Barrow; Randa Razzouk
Journal:  Pediatr Nephrol       Date:  2020-02-14       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.